{"nctId":"NCT00267670","briefTitle":"Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH","startDateStruct":{"date":"2005-03"},"conditions":["Nonalcoholic Steatohepatitis","Liver Diseases"],"count":26,"armGroups":[{"label":"Pentoxifylline","type":"EXPERIMENTAL","interventionNames":["Drug: Pentoxifylline"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Pentoxifylline","otherNames":["Trental"]},{"name":"Placebo","otherNames":["sugar pill"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subjects must be willing to give written informed consent\n2. Diagnosis of steatohepatitis Grade \\>= 1 (Brunt et al. criteria - Am J Gastroenterology 1999;94(9)2467-74) on biopsy within 6 months prior to entry into protocol\n3. No histologic evidence of cirrhosis\n4. Persistent ALT elevation (\\> 1.5 the upper limit normal) over 6 months prior to entry into study\n5. Adult subjects 18-65 years of age of any race or gender\n6. Compensated liver disease with the following hematologic, biochemical, and serological criteria on entry into protocol:\n\n   * Hemoglobin \\> 11 gm/dL for females and \\> 12 gm/dL for males\n   * White blood cell (WBC) \\> 2.5 K/UL\n   * Neutrophil count \\> 1.5 K/UL\n   * Platelets \\> 100 K/UL\n   * Direct bilirubin, within normal limits\n   * Indirect bilirubin within normal limits (unless non-hepatitis factors such as Gilbert's disease explain indirect bilirubin rise. In such cases total bilirubin must be \\< 3.0 mg/dL)\n   * Albumin \\> 3.2 g/dL\n   * Serum creatinine within normal limits\n7. Hemoglobin A1c (HgbA1c) \\< 7%\n8. Antinuclear antibodies (ANA) \\< 1:160\n9. Anti-smooth muscle Ab negative\n10. Serum hepatitis B surface antigen (HepBsAg) negative\n11. Serum hepatitis C antibody (HepC Ab) negative\n12. Iron/total iron binding capacity (TIBC) ratio (transferrin saturation) \\< 45%\n13. Alpha-1-antitrypsin level within normal limits\n14. Ceruloplasmin level within normal limits\n15. Negative pregnancy test (females)\n16. Concomitant use of lipid lowering agents at study entry will not exclude patients from the study.\n\nExclusion Criteria:\n\n1. Evidence of decompensated cirrhosis\n2. Active gastrointestinal (GI) bleeding\n3. Renal failure (creatinine clearance \\< 80 mL/min)\n4. Active alcohol or drug abuse\n5. Uncontrolled diabetes (HgbA1c \\> 7)\n6. Current treatment with anti-diabetic medications such as thiazolidinediones or metformin (stable doses of sulfonylureas are acceptable)\n7. Current treatment with anti-TNF alpha medication (i.e. Remicade or Enbrel)\n8. Current treatment with vitamin E\n9. Alcohol consumption \\< 20 g/day (males) or \\< 10 g/day (females) - assessed by one physician and confirmed with one family member.\n10. HIV positive status\n11. Any history of cerebral and/or retinal hemorrhage\n12. Prior intolerance of pentoxifylline or any other methylxanthine (i.e. caffeine, theophylline, or theobromine)\n13. Current use of theophylline\n14. Known diagnosis of malignancy\n15. Any other conditions which the investigator feels would make the subject unsuitable for enrollment, or could interfere with the subject completing the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Participants With a 30% Reduction in Alanine Aminotransferase (ALT) Treated With Pentoxifylline (PTX) or Placebo for 12 Months.","description":"The primary goal of the study was to determine whether pentoxifylline (PTX) therapy improved serum ALT (\\> or = 30% change from baseline to month 12) compared to placebo.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"The Effect of Pentoxifylline on Change in Tumor Necrosis Factor [TNF]-α Levels in Patients With NASH","description":"The mean change from baseline to month 12 in proinflammatory cytokines (such as TNF-α) and gene expresssion were the secondary endpoints and were analyzed with the same analysis of covariance model and summary statistics specified for the primary endpoint. Differences were regarded as statistically significant when P \\< 0.05. The results for TNF-α are reported here. Interleukin-6 \\[IL-6\\], IL-10) and expression of TNF-alpha Receptors (p55 and p75) had insufficient data for statistical analysis.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-117.9","spread":"109.5"},{"groupId":"OG001","value":"18.3","spread":"64.4"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Leptin Levels in Patients Treated With Pentoxifylline or Placebo for 12 Months","description":"Values represent changes in leptin from baseline to 12 months in patients treated with pentoxifylline or placebo.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"0.07"},{"groupId":"OG001","value":"0.78","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Adiponectin Levels in Patients Treated With Pentoxifylline or Placebo for 12 Months","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.3"},{"groupId":"OG001","value":"0.8","spread":"0.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":[]}}}